Atrial Fibrillation
Read Time: 2 mins

17/Convergent approach to persistent atrial fibrillation ablation – single-centre safety and efficacy

Copy Link
Published Online: Oct 2nd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr17
Authors: A Carpenter (Presenting Author) - University Hospitals Bristol, Bristol, UK; SIA Rizvi - University Hospitals Bristol, Bristol, UK; K Maciver - University Hospitals Bristol, Bristol, UK; C Rajakaruna - University Hospitals Bristol, Bristol, UK; F Ciulli - University Hospitals Bristol, Bristol, UK; E Duncan - University Hospitals Bristol, Bristol, UK; G Thomas - University Hospitals Bristol, Bristol, UK; P Barman - University Hospitals Bristol, Bristol, UK; R Bond - University Hospitals Bristol, Bristol, UK; I Diab - University Hospitals Bristol, Bristol, UK; A Nisbet - University Hospitals Bristol, Bristol, UK
Quick Links:
Article Information

Introduction: Efforts to maintain sinus rhythm in patients with persistent atrial fibrillation (PsAF) remain challenging with sub-optimal long term outcomes seen with anti-arrhythmic medication, catheter ablation and stand-alone surgical approaches. For patients with a significant symptomatic burden this remains an unmet need. The convergent approach entails thoracoscopic epicardial left atrial (LA) posterior wall radiofrequency ablation followed by endocardial catheter pulmonary vein isolation (PVI). This exciting new approach is evaluated in terms of efficacy and safety.

Methods: All patients undergoing convergent PsAF ablation at our centre were analysed. The Atricure Epi-Sense® system was used to deliver LA posterior wall radiofrequency ablation via trans-diaphragmatic, pericardial window access under direct endoscopic visualisation and with oesophageal temperature monitoring under general anaesthesia. Follow-on endocardial ablation was undertaken using radiofrequency PVI via trans-septal puncture with or without additional ablation.
Electro-anatomical mapping software was used. Demographic,
arrhythmia and procedural data were collected. Safety outcomes including peri-operative complications, death and stroke/transient ischaemic attack (TIA), as well as efficacy outcomes including freedom from documented or symptomatic AF were collected at 3-,6- and 12-months.

Results: From June 2017–March 2019, 24 patients underwent convergent PsAF ablation. Patient characteristics, procedure and outcome data shown in Table 1 below. Twenty-one (84%) were male with a median age of 63. Twelve (50%) were obese. Hypertension, obstructive sleep apnoea, diabetes and a smoking history were present in 46%, 17%, 8% and 38%, respectively. The majority (71%) had a CHA2DS2VASC score of 0–1. 71% had a severely dilated left atrium and the majority (63%) had preserved left ventricular function. Eighteen (75%) had AF duration >2 years with most (83%) reporting EHRA 2b (moderate) symptom burden.

A median of 25 (IQR 12; range 13–41) surgical lesions were delivered with 2 days median inpatient stay. Post-operative complications were minimal; See Table 2. Most percutaneous ablations consisted of PVI with or without roof line or floor lesions (21%, 21%, 42% respectively). Seventeen percent underwent more extensive electro-anatomically guided ablation. There were no endocardial procedure complications. There were three redo endocardial procedures within 12 months and one ablation for atrial tachycardia. At 12 months, all patients were alive with no new stroke/TIA. Freedom for documented or symptomatic AF at 3-, 6- and 12-months was 75%, 63% and 63%, respectively.

ConclusionsOur data suggest convergent AF ablation is effective with excellent immediate and long-term safety outcomes in a real-world cohort of patients with a significant duration of AF and evidence of established atrial remodelling. Freedom from AF at 12 months compares very favourably with existing techniques. Our safety and mortality data demonstrate good outcomes when compared with existing studies of convergent ablation. There was a low rate of re-do procedures or further ablation for related arrhythmia. Convergent AF ablation appears to offer a safe and effective option for those who are unlikely to benefit from existing therapeutic strategies for maintaining sinus rhythm and further evaluation of this exciting technique is warranted.

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72